Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
AssigneeAventis Pharma S.A.
InventorsChamsy Sarkis, Jacques Mallet
Life of this patent
Estimating the term…
Abstract
The invention concerns novel recombinant viruses and their use for gene-transfer into nerve cells of vertebrates. The invention also concerns pharmaceutical compositions comprising said recombinant viruses. More particularly, the invention concerns novel vectors derived from baculoviruses and their use for treating diseases of the nervous system of vertebrates.
Claims6
A method for expressing a polypeptide preferentially in glial cells of the central nervous system, the method comprising administering stereotaxically into the central nervous system of a subject a recombinant baculovirus, said baculovirus having a baculovirus envelope protein and comprising a heterologous nucleic acid sequence encoding the polypeptide operatively associated with a CMV (cytomegalovirus) promoter, thereby causing expression of the polypeptide preferentially in glial cells.
Dependencies are inferred from the claim text.